42
Views
20
CrossRef citations to date
0
Altmetric
Research Article

The Effects of Intravenous Iron Treatment on Oxidant Stress and Erythrocyte Deformability in Hemodialysis Patients

, , , , , , & show all
Pages 77-82 | Published online: 09 Jul 2009

  • Cavdar C". Camsari T. Senunn I. Gönenc S and Acikgöz O. Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human crythropoietin. Scand J Urol Nephrol 1997: 31: 371-5.
  • Richard M. Arnaud J. Jurkovitz C et al. Trace elements and lipid peroxidation abnunnalities in patients with chronic renal failure. Nephron 1991: 57: 10-15.
  • Matkovies B. Laszlo A, Varga SZ et al. Changes and correlations of antioxidant enzymes, lipid peroxidation and serum neutral lipids due to haemodialysis treatment in chronic uraemic patients. Int Urol Nephrol 1988: 20(5): 559- 64.
  • Vijoen M, Oliveria A. Milne F. Physical properties of the red blood cells in chronic renal failure. Nephron 1991: 59: 271-8.
  • Rosemmund A. Binsvvanger L. Strub PW et al. Oxidative injury to erythrocytes. red cell rigidity and splenic heniolysis in hemndiayzed uremic patients. Ann Intern Med 1975: 82(4): 460 5.
  • Zachee P. Ferrant A. Daelemans R et al Oxidative injury to erythrocytes. cell rigidity and splenic hemolysis in hemodialyzed patients before and during erythroprotein treatment' Nephron 1993: 65: 288-93.
  • Sommerburg O, Grune T. Hampl H et al. Does long-term treatment of renal anaemia with recombinant erythroprotein influence oxidative stress in haemodialysed patients' Nephrol Dial Transplant 1998: 13: 2583 7
  • Lim P, Wei YH. Yu YL and Kho B Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephro'l Dial Transplant 1999: 14: 2680-7.
  • Fishbane S, Maesaka JK and MittaI SK. Is there material hazard in treatment with intravenous iron'.' Nephrol Dial Transplant 1999; 14: 2595-8.
  • Koutsouris D. Guillet D. Lexievre Ret al. Individual red blood cell transit times during How through cylindrical microporex. Clin Hemorheol 1988: 8: 453-60.'
  • Jain SK. Membrane lipid peroxidation in erythrocytes of the newborn. Clinica Chemica Acta 1986; 161: 301 6.
  • Silverberg DS. Blum M. Peer G. Kaplan E and laina A. Intravenous ferric saccharaic as an iron supplement in dialysis patients. Nephron 1996; 72: 413-7.
  • European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14(Suppl 5): 1-50.
  • Worvvood M. Pathogenesis and management of haemochromatosis. Br J Haematol 1999; 105(Suppl 18: 16-8
  • Bayes B. Sierra C. Pastor MC and Bonal I. Effect of intravenous iron therapy on oxidative stress in hemodialysis. Nephrol Dial Transplant 1998: 13(6): A206.
  • Geisser P. Baer M and Schath E. Structure/histotoxicity relationship of parenteral iron preparations. Drug Res 1992: 42(1): 1439-52.
  • Forman S, Bisehel M, Hochstein P, Erythrocyte defornability in uremic hemodlialysed patients. Ann lnterm Med 1473: 79: 841 3.
  • Here Go. lfon ET, Ebong PE and Umoh IB. Abnorm alities in adenosine triphusphatase of the erhrocyte membrane in iron delicieney anaemia. J Trace Elem Med Biol 1996; 10 (3): 185-8.
  • Browne PV. Shaley O. Kuypers FA et al. Removal of erythrcyte membrane iron in vivo ameliorates the pathobiology of murine thalussemia. J Clim Invest 1907 Sep 15: 100(6): 1459-64.
  • Maninz M, Vava A. Alvarino J et al. Hemorheological alterations in patients with chronic renal failure. Effect of hemodyalysis Clin Hemorheol Microcire 1999 21(1): 1-6.
  • Maedougall IC. Intravenous administration of iron in epoelin-treated haemodialysis patienis-which drugs, which regimen? Nephrol Dial Transplant 2000: 15; 1743-5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.